Clinical Education InitiativeMenu
Search
Home > Courses > Addressing the Rise of Non-AIDS Defining Cancers: Implications for Cancer Screening & Treatment

Addressing the Rise of Non-AIDS Defining Cancers: Implications for Cancer Screening & Treatment

Addressing the Rise of Non-AIDS Defining Cancers: Implications for Cancer Screening & Treatment
Addressing the Rise of Non-AIDS Defining Cancers: Implications for Cancer Screening & Treatment
Play
Sorry, this learning module is not available for mobile devices.
Resource ID: CM391
Original Presentation: 9/8/2015
Web Posting: 1/15/2016
CE Expiration: 09/07/2018
Presenter
  • Missak Haigentz, Jr., MD
    Associate Professor of Clinical Medicine
    Albert Einstein College of Medicine, New York, NY and Montefiore Medical Center, Bronx, NY
Learning Objectives
At the completion of this educational session, participants will:
  1. Appreciate the changing epidemiology of cancer in the era of combination antiretroviral therapy.
  2. Understand reasons for cancer care disparities in this population.
  3. Be aware of current challenges in cancer care (prevention, screening and treatment), focusing on lung cancer, for persons with HIV infection.
  4. Know about current clinical trials for patients with non-AIDS defining cancers.
Presenter Bio
Missak Haigentz, Jr., MD
Missak Haigentz, is Associate Professor of Clinical Medicine and Otorhinolaryngology at Albert Einstein College of Medicine, and Montefiore Medical Center. His work focuses on clinical trials for the treatment of cancers of the lung, head and neck, including persons with HIV infection. Dr. Haigentz has received the ASCO Clinical Research Career Development Award in 2004 and NIH funding for his research in head and neck cancer. He is the current chair of the Non-AIDS Defining Cancer Working Group of the AIDS Malignancy Consortium and has served on several committees supported by the National Cancer Institute.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on September 8, 2015 and will terminate September 7, 2018.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length. 

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity. 

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose. 
  • Dr. Missak Haigentz (Presenter) had no relevant financial relationships to disclose. Dr. Haigentz submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

PRN Learning Modules